IT1314184B1 - Composizioni farmaceutiche per la terapia di condizioni di stressossidativo - Google Patents

Composizioni farmaceutiche per la terapia di condizioni di stressossidativo

Info

Publication number
IT1314184B1
IT1314184B1 IT1999MI001817A ITMI991817A IT1314184B1 IT 1314184 B1 IT1314184 B1 IT 1314184B1 IT 1999MI001817 A IT1999MI001817 A IT 1999MI001817A IT MI991817 A ITMI991817 A IT MI991817A IT 1314184 B1 IT1314184 B1 IT 1314184B1
Authority
IT
Italy
Prior art keywords
therapy
stress
pharmaceutical compositions
oxidative conditions
linear
Prior art date
Application number
IT1999MI001817A
Other languages
English (en)
Italian (it)
Inventor
Soldato Piero Del
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of ITMI991817A0 publication Critical patent/ITMI991817A0/it
Priority to IT1999MI001817A priority Critical patent/IT1314184B1/it
Priority to MXPA02001519A priority patent/MXPA02001519A/es
Priority to PT00953102T priority patent/PT1252133E/pt
Priority to RU2002103509/04A priority patent/RU2264383C2/ru
Priority to CA002381409A priority patent/CA2381409A1/en
Priority to PL353451A priority patent/PL203200B1/pl
Priority to ES00953102T priority patent/ES2243292T3/es
Priority to KR1020027001883A priority patent/KR100687809B1/ko
Priority to CNB2006101362310A priority patent/CN100528834C/zh
Priority to EP05104064A priority patent/EP1593664A1/en
Priority to CNB008140499A priority patent/CN1289466C/zh
Priority to EP00953102A priority patent/EP1252133B1/en
Priority to NZ516889A priority patent/NZ516889A/en
Priority to SI200030734T priority patent/SI1252133T1/xx
Priority to AU65670/00A priority patent/AU781643B2/en
Priority to BR0013264-0A priority patent/BR0013264A/pt
Priority to AT00953102T priority patent/ATE297375T1/de
Priority to DE60020741T priority patent/DE60020741T2/de
Priority to DK00953102T priority patent/DK1252133T3/da
Priority to JP2001516885A priority patent/JP2003515526A/ja
Priority to IL14780100A priority patent/IL147801A0/xx
Priority to CA2698353A priority patent/CA2698353A1/en
Priority to US10/048,469 priority patent/US7186753B1/en
Priority to NZ535559A priority patent/NZ535559A/en
Priority to PCT/EP2000/007225 priority patent/WO2001012584A2/en
Priority to KR1020067024051A priority patent/KR100760394B1/ko
Priority to HU0203939A priority patent/HUP0203939A3/hu
Publication of ITMI991817A1 publication Critical patent/ITMI991817A1/it
Priority to ZA200200628A priority patent/ZA200200628B/xx
Priority to NO20020623A priority patent/NO328498B1/no
Application granted granted Critical
Publication of IT1314184B1 publication Critical patent/IT1314184B1/it
Priority to AU2005202824A priority patent/AU2005202824B2/en
Priority to US11/642,783 priority patent/US7399878B2/en
Priority to US12/132,245 priority patent/US7759392B2/en
Priority to NO20093253A priority patent/NO20093253L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C203/00—Esters of nitric or nitrous acid
    • C07C203/02—Esters of nitric acid
    • C07C203/04—Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
IT1999MI001817A 1999-08-12 1999-08-12 Composizioni farmaceutiche per la terapia di condizioni di stressossidativo IT1314184B1 (it)

Priority Applications (33)

Application Number Priority Date Filing Date Title
IT1999MI001817A IT1314184B1 (it) 1999-08-12 1999-08-12 Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AT00953102T ATE297375T1 (de) 1999-08-12 2000-07-27 Pharmazeutische verbindungen
DE60020741T DE60020741T2 (de) 1999-08-12 2000-07-27 Pharmazeutische verbindungen
RU2002103509/04A RU2264383C2 (ru) 1999-08-12 2000-07-27 Лекарственные вещества и фармацевтические композиции на их основе для использования в случаях окислительного стресса
CA002381409A CA2381409A1 (en) 1999-08-12 2000-07-27 Nitric ester derivatives
PL353451A PL203200B1 (pl) 1999-08-12 2000-07-27 Związki farmaceutyczne, ich zastosowanie, formulacje farmaceutyczne, ester 4'-acetyloaminofenylowy kwasu 4-nitroksymasłowego oraz zastosowanie tego estru
ES00953102T ES2243292T3 (es) 1999-08-12 2000-07-27 Compuestos farmaceuticos.
KR1020027001883A KR100687809B1 (ko) 1999-08-12 2000-07-27 약제화합물들
CNB2006101362310A CN100528834C (zh) 1999-08-12 2000-07-27 药用化合物
EP05104064A EP1593664A1 (en) 1999-08-12 2000-07-27 Nitric esters derivatives of ferulic acid and sulindac with pharmaceutical activity
CNB008140499A CN1289466C (zh) 1999-08-12 2000-07-27 药用化合物
EP00953102A EP1252133B1 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
NZ516889A NZ516889A (en) 1999-08-12 2000-07-27 Pharmaceutical compounds useful in oxidative stress and/or endothelial dysfunction of moderate intensity
SI200030734T SI1252133T1 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
AU65670/00A AU781643B2 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
BR0013264-0A BR0013264A (pt) 1999-08-12 2000-07-27 Compostos ou seus sais, uso dos mesmos, e, formulações farmacêuticas
MXPA02001519A MXPA02001519A (es) 1999-08-12 2000-07-27 Compuestos farmaceuticos.
DK00953102T DK1252133T3 (da) 1999-08-12 2000-07-27 Farmaceutiske forbindelser
PT00953102T PT1252133E (pt) 1999-08-12 2000-07-27 Compostos farmaceuticos
JP2001516885A JP2003515526A (ja) 1999-08-12 2000-07-27 医薬化合物
IL14780100A IL147801A0 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
CA2698353A CA2698353A1 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
US10/048,469 US7186753B1 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
NZ535559A NZ535559A (en) 1999-08-12 2000-07-27 Pharmaceutical compounds useful in oxidative stress and/or endothelial dysfunction of moderate intensity
PCT/EP2000/007225 WO2001012584A2 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds
KR1020067024051A KR100760394B1 (ko) 1999-08-12 2000-07-27 약제화합물들
HU0203939A HUP0203939A3 (en) 1999-08-12 2000-07-27 Pharmaceutical compounds and compositions containing them and their use
ZA200200628A ZA200200628B (en) 1999-08-12 2002-01-23 Pharmaceutical compounds.
NO20020623A NO328498B1 (no) 1999-08-12 2002-02-08 Forbindelser, farmasoytiske formuleringer inneholdende slike, og anvendelse av forbindelsene til fremstilling av legemidler
AU2005202824A AU2005202824B2 (en) 1999-08-12 2005-06-28 Pharmaceutical compounds
US11/642,783 US7399878B2 (en) 1999-08-12 2006-12-21 Pharmaceutical compounds
US12/132,245 US7759392B2 (en) 1999-08-12 2008-06-03 Pharmaceutical compounds
NO20093253A NO20093253L (no) 1999-08-12 2009-10-29 Forbindelser, farmasoytiske formuleringer og anvendelse av forbindelsene til fremstilling av legemiddel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001817A IT1314184B1 (it) 1999-08-12 1999-08-12 Composizioni farmaceutiche per la terapia di condizioni di stressossidativo

Publications (3)

Publication Number Publication Date
ITMI991817A0 ITMI991817A0 (it) 1999-08-12
ITMI991817A1 ITMI991817A1 (it) 2001-02-12
IT1314184B1 true IT1314184B1 (it) 2002-12-06

Family

ID=11383554

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI001817A IT1314184B1 (it) 1999-08-12 1999-08-12 Composizioni farmaceutiche per la terapia di condizioni di stressossidativo

Country Status (23)

Country Link
US (3) US7186753B1 (enExample)
EP (2) EP1593664A1 (enExample)
JP (1) JP2003515526A (enExample)
KR (2) KR100760394B1 (enExample)
CN (2) CN100528834C (enExample)
AT (1) ATE297375T1 (enExample)
AU (1) AU781643B2 (enExample)
BR (1) BR0013264A (enExample)
CA (2) CA2381409A1 (enExample)
DE (1) DE60020741T2 (enExample)
DK (1) DK1252133T3 (enExample)
ES (1) ES2243292T3 (enExample)
HU (1) HUP0203939A3 (enExample)
IL (1) IL147801A0 (enExample)
IT (1) IT1314184B1 (enExample)
MX (1) MXPA02001519A (enExample)
NO (2) NO328498B1 (enExample)
NZ (2) NZ516889A (enExample)
PL (1) PL203200B1 (enExample)
PT (1) PT1252133E (enExample)
RU (1) RU2264383C2 (enExample)
WO (1) WO2001012584A2 (enExample)
ZA (1) ZA200200628B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
IT1288123B1 (it) 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
IT1317735B1 (it) * 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
IT1319202B1 (it) * 2000-10-12 2003-09-26 Nicox Sa Farmaci per le malattie a base infiammatoria.
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2008201838B2 (en) * 2001-05-02 2010-07-29 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
ITMI20011307A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per l'epilessia
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
EP1497268A4 (en) * 2002-04-05 2006-01-18 Nitromed Inc NITROGEN OXIDE DISPENSER, COMPOSITIONS AND METHOD OF USE
US7288535B2 (en) 2002-05-02 2007-10-30 Osteoscreen, Inc. Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
JP2005539089A (ja) * 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003254282A1 (en) 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
ITMI20021861A1 (it) * 2002-08-29 2004-02-29 Nicox Sa Procedimento di sintesi di nitrossialchilesteri di acidi carbossilici, intermedi impiegabili in detto procedimento e loro preparazione.
ITMI20022658A1 (it) 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
US7166638B2 (en) 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7169805B2 (en) 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
WO2004110432A1 (en) 2003-06-19 2004-12-23 Nicox S.A. Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
ATE399757T1 (de) 2003-11-20 2008-07-15 Nicox Sa Neues verfahren zur herstellung von nitrooxyderivaten von paracetamol
JP2007513113A (ja) * 2003-12-02 2007-05-24 ニコックス エス エイ 抗高血圧薬剤のニトロオキシ誘導体
DK1691804T3 (da) * 2003-12-02 2007-07-16 Nicox Sa Nitrooxydderivater af carvedilol og andre beta-blokkere som antihypertensive lægemidler
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
KR100503443B1 (ko) * 2004-02-02 2005-07-22 한림제약(주) 광학적으로 활성인 세티리진 또는 그의 염의 제조방법
WO2006008196A1 (en) 2004-07-20 2006-01-26 Nicox S.A. Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof
AU2005281359A1 (en) 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
KR101450653B1 (ko) * 2006-07-18 2014-10-14 안티브 홀딩스 인크. 비스테로이드 항염증제의 황화수소 유도체
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
RU2340597C1 (ru) * 2007-03-21 2008-12-10 Институт физиологически активных веществ Российской Академии наук Нитроксиалкиламинокислоты
US20080317673A1 (en) * 2007-06-20 2008-12-25 Fatema Salem Al-Thallab Method for diagnosing and treating bronchial asthma
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
WO2009007230A1 (en) 2007-07-09 2009-01-15 Nicox S.A. Use of nitric oxide releasing compounds in the treatment of chronic pain
EP2188245B1 (en) 2007-08-17 2013-11-06 Council of Scientific & Industrial Research Nitric oxide releasing derivatives of paracetamol
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EP3090739A1 (en) 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions composed of naproxen sodium and nizatidine
RU2364394C1 (ru) * 2008-03-19 2009-08-20 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции клопидогрелем при l-name индуцированном дефиците оксида азота
JP2011523941A (ja) * 2008-05-15 2011-08-25 メルク・シャープ・エンド・ドーム・コーポレイション アンギオテンシンｉｉ受容体アンタゴニスト
CA2728301A1 (en) * 2008-07-03 2010-01-07 Osteogenex Inc. Vinpocetine and eburnamonine derivatives for promoting bone growth
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
HRP20140929T1 (hr) 2008-08-01 2014-12-05 Onconox Aps Antitumorska svojstva no-modificiranih inhibitora proteaze
WO2010108843A1 (en) 2009-03-27 2010-09-30 Nicox S.A. Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies
FR2953145B1 (fr) * 2009-11-30 2013-07-19 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux
CN101863900B (zh) * 2010-06-29 2012-07-25 天津药物研究院 一氧化氮供体型噻吩并吡啶衍生物、其制备方法和用途
CN102442908A (zh) * 2010-10-14 2012-05-09 天津药物研究院 制备萘普西诺的中间体及方法
JP5044059B2 (ja) * 2010-11-02 2012-10-10 公益財団法人名古屋産業科学研究所 トランス−２−デセン酸誘導体及びこれを含有する医薬
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
CN102557967A (zh) * 2011-12-28 2012-07-11 合肥科尚医药科技有限公司 一种盐酸氨溴索的制备方法
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10881654B2 (en) 2015-04-24 2021-01-05 University Of Louisville Research Foundation, Inc. Selective PFKFB4 inhibitors for the treatment of cancer
US11420995B2 (en) 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
CA3073952A1 (en) 2017-08-31 2019-03-07 University Of Louisville Research Foundation, Inc. Quinoline derivative, compositions comprising this compound and uses thereof in the treatment of cancer
US10774046B2 (en) 2017-10-26 2020-09-15 University Of Louisville Research Foundation, Inc. Inhibitors for the treatment of cancer and related methods
RU2709067C1 (ru) * 2018-07-23 2019-12-13 федеральное государственное бюджетное образовательное учреждение высшего образования "Тольяттинский государственный университет" Способ термосиловой обработки длинномерных осесимметричных деталей и устройство для его осуществления
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
CN112316158B (zh) * 2020-11-19 2021-09-21 四川大学 一种利用超分子包合剂关闭胶原溶液中抗菌剂活性的方法
CN116270562B (zh) * 2022-03-18 2025-07-01 北京诺和德美医药科技有限公司 一种制备稳定的吸入用2-氨基-3,5-二溴苯甲胺衍生物溶液的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
ATE2269T1 (de) 1978-12-21 1983-02-15 Gruppo Lepetit S.P.A. 3h-naphtho(1,2-d)imidazole, verfahren zu deren herstellung, verbindungen zur verwendung als entzuendungshemmende und antimikrobielle mittel und sie enthaltende zusammensetzungen zu dieser verwendung.
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
JP3775796B2 (ja) * 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
RU2145595C1 (ru) * 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
JPH09202764A (ja) * 1996-01-24 1997-08-05 Chugai Pharmaceut Co Ltd ニトロ化合物
IT1285770B1 (it) 1996-10-04 1998-06-18 Nicox Sa Composti corticoidei
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1311923B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo

Also Published As

Publication number Publication date
ZA200200628B (en) 2003-06-25
CA2698353A1 (en) 2001-02-22
HUP0203939A2 (hu) 2003-03-28
NO328498B1 (no) 2010-03-01
IL147801A0 (en) 2002-08-14
CN1923797A (zh) 2007-03-07
DK1252133T3 (da) 2005-08-15
NO20020623L (no) 2002-04-09
US20090170941A1 (en) 2009-07-02
US20070197499A1 (en) 2007-08-23
US7759392B2 (en) 2010-07-20
DE60020741T2 (de) 2005-12-15
PL203200B1 (pl) 2009-09-30
US7186753B1 (en) 2007-03-06
HUP0203939A3 (en) 2004-12-28
NO20020623D0 (no) 2002-02-08
ES2243292T3 (es) 2005-12-01
CN1289466C (zh) 2006-12-13
PT1252133E (pt) 2005-08-31
EP1593664A1 (en) 2005-11-09
NZ516889A (en) 2004-10-29
NZ535559A (en) 2005-12-23
RU2264383C2 (ru) 2005-11-20
BR0013264A (pt) 2002-04-16
KR100760394B1 (ko) 2007-09-19
AU781643B2 (en) 2005-06-02
PL353451A1 (en) 2003-11-17
JP2003515526A (ja) 2003-05-07
EP1252133A2 (en) 2002-10-30
KR100687809B1 (ko) 2007-02-28
KR20020032552A (ko) 2002-05-03
MXPA02001519A (es) 2002-07-02
EP1252133B1 (en) 2005-06-08
CN100528834C (zh) 2009-08-19
CN1433396A (zh) 2003-07-30
AU6567000A (en) 2001-03-13
KR20060126846A (ko) 2006-12-08
DE60020741D1 (de) 2005-07-14
ATE297375T1 (de) 2005-06-15
WO2001012584A3 (en) 2002-08-29
ITMI991817A0 (it) 1999-08-12
ITMI991817A1 (it) 2001-02-12
WO2001012584A2 (en) 2001-02-22
CA2381409A1 (en) 2001-02-22
US7399878B2 (en) 2008-07-15
NO20093253L (no) 2002-04-09

Similar Documents

Publication Publication Date Title
DK1252133T3 (da) Farmaceutiske forbindelser
IL205420A (en) Immunogoldular and Derivative Compounds, Pharmaceutical Compounds in the Treatment of Inflammatory Stomach and Gastrointestinal Disorders
NO20014925D0 (no) Farmasöytiske forbindelser
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ATE153337T1 (de) Thienopyridinderivate und diese enthaltende pharmazeutische zubereitungen
ES2096073T3 (es) Derivado de benzamida.
DE69921151D1 (de) Fluorszierende marker
FI102896B1 (fi) Menetelmä farmaseuttisesti aktiivisen, rikkiä sisältävän heterosyklisen yhdisteen valmistamiseksi
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
EA200100916A1 (ru) Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
NO982873D0 (no) 1-metylkarbapenemderivater
NO985202D0 (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
ATE110569T1 (de) Pharmazeutische zusammensetzung zur verbesserung von dysuria.
WO2000027378A3 (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
ATE94050T1 (de) Mittel zur verhinderung von zahnbelagbildung.